Approximately 450 patients will be randomized to receive CORLUX® (Mifepristone) or placebo for 7 days followed by antidepressant. The purpose is to compare the efficacy of CORLUX followed by antidepressant versus placebo followed by antidepressant in reducing psychotic symptoms in patients with a diagnosis of psychotic depression.
Major Depression With Psychotic Features
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of CORLUX (Mifepristone) vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features|